A Study of Stapokibart Injection in Patients With Atopic Dermatitis (AD)
Recruiting
Observational Study
Atopic Dermatitis (AD)
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 1,000 (estimated)
- Sponsor
- Chengdu Kangnuoxing Biopharma,Inc. · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This study is an open label, prospective study to evaluate the safety and efficacy of Stapokibart Injection in patients with AD.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Trial participants aged 18 years or older at baseline, with no restrictions on gender.
* Physician decision to treat trial participants with Stapokibart Injection for AD (according to the China-specific prescribing information) made prior to and independently of the participan…
Contacts